Gout medication list: Acute flare and urate-lowering options

Key takeaways

A gout medication list covers two separate jobs. One settles the acute flare, the other lowers serum uric acid to prevent the next one.

NSAIDs and low-dose colchicine are first line for an acute attack. Corticosteroids are the alternative when those are contraindicated.

Allopurinol is the first-line urate-lowering therapy. Start at 100 mg daily and titrate toward a serum uric acid below 6 mg/dL.

Renal function, drug interactions and cardiovascular history decide which agent is safe for a given patient.

Practice management software like Pabau holds the regimen, the monitoring schedule and the lab results on one patient record.

A gout medication list is a clinical reference setting out every drug used to treat gout, with its dose, route and monitoring requirement.

It splits into two halves. One half settles the acute flare, the other lowers serum uric acid so the next flare never starts.

Mixing the two halves up costs the patient weeks. Allopurinol does nothing for an attack already in progress, and an NSAID does nothing about the crystals that caused it. The order matters as much as the choice of drug.

Below are the acute agents with their doses, and the urate-lowering options with their titration and monitoring rules. A five-step routine for working through the list in a consultation follows.

What is a gout medication list?

Gout happens when monosodium urate crystals build up in a joint and set off an inflammatory response. Managing it takes two things at once. Symptoms have to be controlled during the flare, and uric acid has to come down and stay down between flares.

The list records the same fields for every agent: drug name, strength, route, frequency, monitoring requirement and review date. Written that way, it works as a prescribing check and as the documentation the note needs. The chart below sets out both tracks with the doses used in this article.

According to the American College of Rheumatology (ACR), clinicians should pick agents on patient factors such as renal function, contraindications and prior responses. The reference earns its place in primary care, urgent care and rheumatology practices seeing gout every week.

Medications for acute gout flares

Acute flare treatments come first on the list. These agents work quickly to reduce pain, swelling and joint inflammation during an active attack. Three medication classes dominate acute gout management: NSAIDs, colchicine and corticosteroids.

• NSAIDs (non-steroidal anti-inflammatory drugs): Indomethacin, naproxen and ibuprofen are the first-line choices. Typical starting doses run from 50 mg three times daily for indomethacin to 500 mg twice daily for naproxen. NSAIDs work within hours but carry gastrointestinal and renal risks, particularly in patients over 65 or with existing kidney disease.
• Colchicine: The approved low-dose regimen is 1.2 mg at symptom onset, then 0.6 mg one hour later. It is preferred over historical high-dose protocols. Colchicine has a narrow therapeutic window and interacts with several drug classes, particularly statins and macrolide antibiotics.
• Corticosteroids: Oral prednisone at 30-40 mg daily for 5-7 days, or intramuscular triamcinolone at 40 mg, serve as alternatives when NSAIDs or colchicine are contraindicated. Steroid efficacy rivals NSAIDs, but prolonged use carries metabolic risks.

Any complete list should note the contraindications for each class. NSAIDs are avoided in patients with active peptic ulcer disease or significant renal impairment. Colchicine needs a dose adjustment in renal failure, and corticosteroids can worsen glycemic control in diabetic patients.

Those checks are easier to make in the moment than to remember afterwards. Prescription management software holds the strength, frequency and route against the patient record and warns about allergies and interactions before the script goes out.

Urate-lowering therapy for long-term prevention

Long-term prevention depends on medications that lower serum uric acid below the target of 6 mg/dL. This half of the list covers xanthine oxidase inhibitors, uricosuric agents and one biologic option.

• Allopurinol: First-line urate-lowering therapy. The starting dose is 100 mg daily, titrated in 100 mg increments every 2-4 weeks until the target uric acid is reached. Standard maintenance runs from 200 to 600 mg daily. HLA-B*5801 screening is recommended in high-risk ethnic populations before starting, because of the hypersensitivity syndrome risk.
• Febuxostat (Uloric): A second-line xanthine oxidase inhibitor. The typical dose is 40 mg daily, increased to 80 mg if needed. An FDA black box warning covers cardiovascular risk with febuxostat, and that warning must be documented when prescribing.
• Probenecid: A uricosuric agent that increases renal uric acid excretion. The usual dose is 250-500 mg twice daily. It is contraindicated in patients with uric acid overproduction or significant renal impairment (eGFR <50 mL/min).
• Pegloticase (Krystexxa): A biologic reserved for refractory or tophaceous gout. It is given as an 8 mg intravenous infusion every 2 weeks, and only when conventional therapies have failed. It requires premedication and careful monitoring for infusion reactions.

The NICE clinical knowledge summary on gout stresses that urate-lowering therapy starts after the acute attack resolves. It is reserved for patients who have had recurrent episodes. A printed list helps confirm the timing and the sequence of these agents.

Over-the-counter and adjunctive options

Many patients try to self-manage with over-the-counter NSAIDs before they seek clinical care. Ibuprofen at 200-400 mg three times daily and naproxen at 220 mg twice daily are widely available, though both are weaker than prescription-strength formulations. Note on the list that these options do nothing for long-term prevention and can delay urate-lowering therapy.

Dietary supplements such as vitamin C and tart cherry extract have mixed evidence behind them. Lifestyle changes across fluid intake, dietary purines and alcohol do support medical therapy. Neither belongs on the list as a primary prevention method, because neither replaces a urate-lowering drug.

How to use the list in clinical practice

1. Confirm the diagnosis: Use joint aspiration with crystal analysis, or clinical criteria. Those criteria are joint pain, swelling and an elevated serum uric acid.
2. Assess acute versus preventive phase: Decide whether the patient has an active flare or is in remission. A flare needs immediate anti-inflammatory therapy. Remission is when urate-lowering therapy starts.
3. Screen for contraindications: Review renal function (eGFR), gastrointestinal history, cardiovascular history and drug interactions, especially between colchicine and statins, before selecting an agent.
4. Set the uric acid target: Aim for a serum uric acid below 6 mg/dL. Monitor levels every 2-4 weeks during titration and adjust the dose on lab results and clinical response.
5. Document the monitoring plan: Record baseline creatinine, uric acid and liver function tests. Schedule repeat labs 2-4 weeks after starting or changing urate-lowering therapy.

Step five is where most of the follow-up is won or lost. It is also the step that gets rushed at the end of a consultation. An AI medical scribe can lift the regimen and the review interval straight out of the conversation, so the note matches what was actually prescribed.

Who the list is for

Primary care clinicians managing hyperuricemia and acute gout get the most out of a structured reference, because they see the condition in short appointments. Practices running on GP clinic software can keep the list beside the patient record. The prescriber then checks it in the same window as the notes.

Rheumatologists treating complex or refractory gout use the same reference to confirm that urate-lowering therapy has been escalated properly. Nurses giving medications in urgent care and walk-in settings rely on it to check dosing safety and patient eligibility.

Pharmacists use it to counsel patients on interactions, dietary considerations and monitoring schedules. A wider medication review catches the rest of the patient’s regimen, which is where the colchicine and statin interaction usually shows up.

What a structured list changes in the practice

Consistency: A standardized list means every clinician in the practice picks medications from the same evidence-based framework. That reduces variation between prescribers and makes outcomes easier to compare.

Documentation clarity: Structured fields for drug name, strength, route, frequency and monitoring schedule create an auditable record. That detail supports regulatory compliance and protects the practice if a dose escalation or an interaction is later questioned.

Faster prescribing: A visual checklist of acute and preventive options speeds up decisions in high-volume settings. Clinicians confirm contraindications and renal adjustments against the list before prescribing, which cuts errors.

Patient safety: Putting the monitored parameters on the list means the follow-up labs get booked. That matters most for allopurinol, with its hypersensitivity monitoring, and febuxostat, with its cardiovascular warning.

How Pabau keeps the regimen and the lab monitoring on one record

In most practices a gout regimen ends up in three places. The dose sits in the consultation note, the lab request sits in the pathology system, and the review date sits in someone’s diary. When the patient comes back, the clinician rebuilds the picture from memory.

Practice management software like Pabau keeps them together. The prescription, the uric acid result and the next review sit on one patient record. The prescriber can see whether the last titration worked before changing the dose. Pabau Scribe, our AI scribe, drafts the note from the consultation itself.

Automated recalls cover the 2-4 week lab checks during titration, and the digital version of this list attaches to the record instead of being printed. Your team stops chasing results, and the patient stops dropping off the follow-up schedule.

Keep every gout regimen on one record

Pabau’s digital forms and patient records hold the medication, the uric acid target and the next lab date together. Your team stops chasing results between visits.

Book a demo

Conclusion

The sequencing is the part worth carrying out of this list. Settle the flare with an NSAID, low-dose colchicine or a steroid. Then start allopurinol once the joint has calmed and the patient has had more than one attack.

What decides the outcome is rarely the first prescription. It is whether the uric acid gets rechecked, the dose gets titrated, and the target below 6 mg/dL is actually reached. Practices lose gout patients between visits, not in the consultation.

So print the list, or hold it in the patient record where the next clinician will see it. Book a demo to see how Pabau keeps the regimen, the lab schedule and the review date on one record.

Continue your research

Need a wider view of the patient’s regimen? Medication review template captures every drug a patient takes, which is where the colchicine and statin interaction shows up.

Prescribing an NSAID for a patient with poor renal function? Acute kidney injury nursing care plan sets out the monitoring an at-risk patient needs.

Recording pain during a flare? Abbey pain scale gives you a structured score for patients who cannot describe the pain themselves.

Comparing systems for a primary care practice? Primary care software walks through what to look for in records, prescribing and patient recall.

Frequently asked questions